SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark seeks arbitration after US company ends pact

14 Dec 2011 Evaluate

Glenmark Pharmaceuticals has sought anarbitration in the US on Napo Pharmaceuticals terminating a collaborationagreement with it to develop and market an HIV-associated diarrhoea drug. NapoPharma had terminated the pact on November 10. The move is a fresh hurdle toGlenmark's ambitious plans to exclusively market the drug, Crofelemer, in 140countries. Glenmark developed Crofelemer with US-based partners Napo and SalixPharmaceuticals. It is the first ever drug developed by an Indian firm.

According to the licensing agreement,Glenmark holds the exclusive rights to distribute Crofelemer in 140 countrieswhile Salix would sell it in regulated markets such as North America, Japan andEurope. Napo Pharma was the initial developer of the molecule and licensed itout to Glenmark and Salix. Glenmark, in a press release, vehemently denied thatNapo had any basis to terminate the agreement and that it was seeking adeclaration from an arbitration panel that Napo’s claims of breach wereunfounded. Glenmark, in August, had filed for arbitration claims against NapoPharma to prevent the latter from distributing Crofelemer in Glenmark’sterritories through relief agencies. Glenmark in July received $15 million fromSalix Pharma towards upgrading the manufacturing facility for Crofelemer and isexpected to get $6.6 million in five equal instalment.

Glenmark Pharma Share Price

2420.05 27.45 (1.15%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×